The date for the generics and biosimilars specialist Sandoz to spin out from its parent company Novartis (NOVN: VX) has been announced. 25 September 2023
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news